title: Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
abstract: BACKGROUND
  The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK.
  
  
  METHODS
  A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5% per year. A full lifetime horizon and third party payer perspective was chosen.
  
  
  RESULTS
  The total cost of NAB-P+GEM was £5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of £30 367/LYG and ICUR of £78 086/QALY, confirmed by PSA.
  
  
  CONCLUSIONS
  The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.
authors: Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
authors: M
authors: M
authors: Gharaibeh
authors: Arizona Cancer Center, University of Arizona, Tucson, AZ 85721, USA.
authors: A
authors: A
authors: McBride
authors: Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
authors: J L
authors: JL
authors: Bootman
authors: 1] Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA [2] Arizona Cancer Center, University of Arizona, Tucson, AZ 85721, USA.
authors: I
authors: I
authors: Abraham
mesh_terms: D000328:Adult; D000418:Albumins / Q000008:administration & dosage / Q000191:economics; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000191:economics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D008390:Markov Chains; D008875:Middle Aged; D018803:Models, Economic; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000191:economics; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000191:economics; D019057:Quality-Adjusted Life Years; D016019:Survival Analysis; D006113:United Kingdom; D000093542:Gemcitabine
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine